Earnings History Data for Xilio Therapeutics (XLO) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Xilio Therapeutics
Xilio Therapeutics Inc. is a biotechnology company which focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company's product candidate includes XTX101, XTX202, XTX301 and XTX401 which are in clinical stage. Xilio Therapeutics Inc. is based in WALTHAM, Mass.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07-11-2024 | PM | XLO | Xilio Therapeutics | 58.00 | -0.22 | -0.25 | 0.00 | 1.03 | -0.26 (-20.15%) |
0.0 | 0.0 (0.00%) |
0.49 - 2.14 | 1,155,799 | 640,000 | 0 | |||
|
|
||||||||||||||||||
| 08-08-2024 | PM | XLO | Xilio Therapeutics | 33.00 | -0.24 | -0.23 | 0.00 | Xilio Therapeutics GAAP EPS of -$0.24, revenue of $2.4M [8/8/2024 8:02 AM] |
0.8765 | 0.02 (1.74%) |
0.81 | -0.05 (-5.97%) |
0.49 - 2.94 | 22,708 | 110,000 | 108 | ||
| 01-04-2024 | AH | XLO | Xilio Therapeutics | 30.00 | -0.64 | -0.62 | 0.00 | Xilio Therapeutics reports Q4 results [4/1/2024 4:54 PM] |
1.51 | -0.02 (-1.31%) |
1.42 | -0.11 (-7.19%) |
0.49 - 3.67 | 2,635,644 | 5,660,000 | 330,890 | ||
| 14-08-2023 | PM | XLO | Xilio Therapeutics | 78.00 | -0.70 | -0.84 | 0.00 | Xilio Therapeutics GAAP EPS of -$0.70 [8/14/2023 9:57 AM] |
2.90 | 0.10 (3.57%) |
0.0 | 0.0 (0.00%) |
1.95 - 4.92 | 7,717 | 0 | 0 | ||
| 09-05-2023 | PM | XLO | Xilio Therapeutics | 86.00 | -0.83 | -0.91 | 0.00 | Xilio Therapeutics GAAP EPS of -$0.83 beats by $0.06 [5/9/2023 8:54 AM] |
3.19 | 0.06 (1.82%) |
0.0 | 0.0 (0.00%) |
1.95 - 4.92 | 10,095 | 10,000 | 0 | ||
| 02-03-2023 | AH | After the close (Mar 2) |
XLO | Xilio Therapeutics | 99.00 | -0.82 | -0.83 | 0.00 | Xilio Therapeutics GAAP EPS of -$0.82 misses by $0.08 [3/2/2023 4:45 PM] |
3.00 | 0.04 (1.52%) |
2.75 | -0.21 (-6.94%) |
1.95 - 9.77 | 20,184 | 40,000 | 1,354 | |
| 09-11-2022 | PM | XLO | Xilio Therapeutics | 60.00 | -0.72 | -0.89 | 0.00 | 2.34 | 0.03 (1.16%) |
2.42 | 0.11 (4.62%) |
2.01 - 27.95 | 3,885 | 30,000 | 100 | |||
|
|
||||||||||||||||||
| 09-08-2022 | PM | 7:30 AM ET (Aug 9) |
XLO | Xilio Therapeutics | 89.00 | -0.90 | -0.78 | 0.00 | Xilio Therapeutics GAAP EPS of -$0.90 [8/9/2022 8:37 AM] |
2.45 | -0.83 (-25.30%) |
2.45 | -0.83 (-25.30%) |
2.04 - 27.95 | 141,890 | 60,000 | 55,958 | |
| 12-05-2022 | PM | 6:30 AM ET (May 12) |
XLO | Xilio Therapeutics | 96.00 | -0.78 | -1.00 | 0.00 | Xilio Therapeutics GAAP EPS of -$0.78 beats by $0.21 [5/12/2022 8:32 AM] |
3.01 | -0.08 (-2.59%) |
3.09 | 0.0 (0.00%) |
2.81 - 27.95 | 39,633 | 40,000 | 268 | |
| 01-03-2022 | PM | XLO | Xilio Therapeutics | 351.00 | -0.98 | -0.94 | 0.00 | Xilio Therapeutics GAAP EPS of -$0.98 misses by $0.06 [3/1/2022 6:39 AM] |
10.96 | -0.82 (-6.96%) |
11.78 | 0.0 (0.00%) |
8.52 - 27.95 | 13,656 | 30,000 | 123 | ||
|
||||||||||||||||||